

10/524979

DT12 Rec'd PCT/PTO 18 FEB 2005

Express Mail No. EV 521025205 US

<b>INFORMATION DISCLOSURE STATEMENT</b>  Address to: Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	WATA-003
	First Named Inventor	TAKEMORI, HIROSHI
	International Application Number	PCT/JP2003/010535
	Confirmation No.	Not yet assigned
	Filing Date	Not yet assigned
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Title:	"SALT-INDUCIBLE KINASE 2 AND USE THEREOF"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

Since each reference is on the order of hundreds of pages in length, for the convenience of the Office and the Examiner, the following references cited on form PTO SB/08A are provided as electronic copies on the CD-ROMs labeled "Copy 1" and "Copy 2":

WO 01/12659 A2; WO 00/73469 A2; and WO 01/81555 A2.


The undersigned hereby certifies that the contents of the CD-ROMs labeled "Copy 1" and "Copy 2" are identical.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 3 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. WATA-003 may be charged thereon.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date:



By:

Carol L. Francis  
Registration No. 38,513

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

10/524979

DT12 Rec'd PCT/PTO 18 FEB 2005

PTO/SB/08a (08-03)

Approved for through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

International Application	PCT/JP2003/010535
Filing Date	Not yet assigned
First Named Inventor	TAKEMORI, HIROSHI
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	WATA-003

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
		US-				
		US-				
		US-				
		US-				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 00/73469 A2	12/07/2000	Sugen Inc.		
		WO 01/12659 A2	02/22/2001	German Human Genome Project		
		WO 01/81555 A2	11/01/2001	Incyte Genomics Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Doi, et al., "Salt-inducible kinase represses cAMP-dependent protein kinase-mediated activation of human cholesterol side chain cleavage cytochrome P450 promoter through the CREB basic leucine zipper domain", The Journal of Biological Chemistry, vol. 277, no 18, issue of May 3, 2002, pp. 15629-15637	
		Feldman, et al., "The salt-inducible kinase, SIK, is induced by depolarization in brain", Journal of Neurochemistry, vol. 74, no. 6, (2000), pp. 2227-2238	
		Horike, et al., "Adipose-specific expression, phosphorylation of ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2", The Journal of Biological Chemistry, vol. 278, no. 20, May 16, 2003, pp. 18440-18447.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

10/524979

DT12 Rec'd PCT/PTO 18 FEB 2005

PTO/SB/08a 08-03

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		International Application	PCT/JP2003/010535
		Filing Date	Not yet assigned
		First Named Inventor	TAKEMORI, HIROSHI
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2 of 2	Attorney Docket Number	WATA-003	

	Lin, et al., "Salt-inducible kinase is involved in the ACTH-cAMP-dependent protein kinase signaling in Y1 mouse adrenocortical tumor cells", Molecular Endocrinology (2001) 15(8), pp. 1264-1276.	
	Mayr, et al., "Transcriptional regulation by the phosphorylation-dependent factor CREB", Nature Reviews, Molecular Cell Biology, vol. 2, August 2001, pp. 599-609.	
	Reusch, et al., "CREB activation induces adipogenesis in 3T3-L cells", Molecular and cellular biology, Feb. 2000, pp. 1008-1020.	
	Saltiel, et al., "Insulin signaling and the regulation of glucose and lipid metabolism", Nature vol. 414, December 13, 2001, pp. 799-806.	
	Sul, et al., "Regulation of fat synthesis and adipose differentiation", progress in nucleic acid research and molecular biology, vol. 60, 1998, pp. 317-345.	
	Tanasijevic, et al., "Phosphorylation of the insulin receptor substrate IRS-1 by casein kinase II", The Journal of Biological Chemistry, vol. 268, no. 24, August 25, 1993, pp. 18157-18166.	
	Wang, et al., "Cloning of a novel kinase (SIK) of the SNF1/AMPK family from high salt diet treated rat adrenal", FEBS letters 453, 1999, pp. 135-139	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.